Zimbabwe has turned down a major US health deal worth 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on confidential biological samples.
The decision came to light after a official document from December was leaked, which showed President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government spokesman later clarified that the United States was requesting health data for research and profit but refused to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more talks to find a agreement agreeable to all parties so the nation's critical HIV programme can proceed.
Broader Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court suspended a related health funding agreement following legal challenges were filed about the security of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had overseen aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral deals to boost transparency and responsibility.
As per reports, Sixteen nations in Africa have so far signed similar health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to surrender its genetic material and health information over an extended period, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"In essence, our country would provide the raw materials for scientific discovery without any certainty that the end products would be accessible to our citizens if a new pandemic arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining frameworks previously established through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This system is intended to ensure that when a country contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We encourage further discussions with our American counterparts on how subsequent collaboration might be structured in a manner that honours the independence and interests of each country."
Medical Community Response
Medical experts stated it understood the government's concerns, but recommended that talks must proceed considering much of the country's Aids initiatives relied on international support.
"In cases where technical issues exist, such as those involving data governance or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," the group commented.
The situation underscores the ongoing challenges between receiving much-needed international aid and safeguarding national sovereignty in an increasingly data-driven world.